≡

Multiplex Assay Kit for Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay)

FLH2; HPLH2; P1; PFP; Pore Forming Protein; Cytolysin; Lymphocyte pore-forming protein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 86-102 98
EDTA plasma(n=5) 89-96 93
heparin plasma(n=5) 91-104 94
sodium citrate plasma(n=5) 84-95 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-102% 89-103% 94-101% 90-105%
EDTA plasma(n=5) 89-97% 92-105% 86-95% 94-101%
heparin plasma(n=5) 94-102% 87-98% 78-104% 98-105%
sodium citrate plasma(n=5) 90-99% 89-104% 88-98% 96-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:PRF1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Diagnostic Microbiology and Infectious Disease Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfection Pubmed:26915636
FASEB JOURNAL The immunoregulatory effects of CD8 T-cell–derived perforin on diet-induced nonalcoholic steatohepatitis Pubmed: 30951375
Theranostics A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors Pubmed: 31695790
Mol Immunol CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection Pubmed: 33223223
INVESTIGATIONAL NEW DRUGS Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors Pubmed: 32772342
Am J Transl Res Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma 34377237
Nat Biomed Eng Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy 34873307
J Exp Med Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion Pubmed:35061012
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPB317Ra01 Recombinant Perforin 1 (PRF1) Positive Control; Immunogen; SDS-PAGE; WB.
APB317Ra01 Active Perforin 1 (PRF1) Cell culture; Activity Assays.
PAB317Ra01 Polyclonal Antibody to Perforin 1 (PRF1) WB; IHC; ICC; IP.
MAB317Ra21 Monoclonal Antibody to Perforin 1 (PRF1) WB; IHC; ICC; IP.
SEB317Ra ELISA Kit for Perforin 1 (PRF1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB317Ra Multiplex Assay Kit for Perforin 1 (PRF1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.